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1. Introduction 
The story of paraoxonase 1 (PON1) begins in 1946, when Abraham Mazur reported the 
presence of an enzyme in human and rabbit tissues which was able to hydrolyse 
organophosphate compounds [1]. In 1950s, enzyme was named "paraoxonase" according to 
its ability to hydrolyse paraoxon, the toxic metabolite of the organophosphate insecticide 
parathion [2,3]. Later it was discovered that it exhibits a broad spectrum of activities and has 
diverse substrates. Mackness and colleagues linked PON1 to cardiovascular diseases in 1991 
and demonstrated that PON1 could prevent the accumulation of oxidized lipids in low-
density lipoprotein (LDL) [4]. However, despite intensive research over sixty years the exact 
physiological function of PON1 is still unclear.  
2. Body 
2.1. Paraoxonase 1 
The paraoxonase (PON) family of the enzymes consists of three members, PON1, PON2 and 
PON3 that share approximately 65% similarity at the amino acid level. These were named in 
order of their discovery, but according to the structural homology and predicted 
evolutionary distance between them it seems that PON2 is the oldest and PON1 is the 
youngest family member [5].  
PON1 and PON3 enzymes are secreted from liver cells and associate with HDL in the 
circulation [6]. Low levels of PON1 may be expressed in a number of tissues, primarily in 
epithelia. PON2 in humans is more widely expressed and is found in nearly every human 
tissue including heart, kidney, liver, lung, placenta, small intestine, spleen stomach, testis [6-
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8]. Also, human PON2 mRNA is detected in the cells of the artery wall, including 
endothelial cells, smooth muscle cells and macrophages and is undetectable in HDL, LDL or 
the media of cultured cells [6, 7]. Of the three PON proteins, PON3 is the most recently 
identified and the least characterized.  
PON1 is the most studied and best understood. This calcium-dependent esterase is 
consisting of 354 amino acids with a molecular mass od approximately 45 kDa [9, 10] and 
requires calcium ions for structural stability and enzymatic activities [11]. It is capable of 
hydrolyzing organophosphates such as oxon metabolites of a insecticides parathion, 
diazinon and chlorpyrihos and nerve agents sarin and soman, aromatic esters such is 
phenyl acetate (arylesterase activity) and a variety of aromatic and aliphatic lactones 
(lactonase activity) [12-18]. Beside its protective role against dietary and environmental 
lactones, PON1 also catalyzes the reaction of lactonization of γ- and δ-hydroxycarboxylic 
acids [18]. It is capable of hydrolyse the oxidised lipid derivates 5-hydroxy-
eicosatetraenoic acid lactone acid (5-HETEL) and 4-hydroxy-docosahexaeonic acid (4-
HDoHE) which are potent triggers of an inflammatory response and therefore 
determinants of atherosclerotic disease [16,19]. 
2.2. Paraoxonase 1 gene polymorphisms  
Genes that code for three PON proteins (pon1, pon2 and pon3) are located to each other on the 
long arm of chromosome 7 in humans (7q21.3-22.1) and share approximately 70% similarity 
at the nucleotide level [8]. Earlier studies on different human populations showed that the 
hydrolytic activity of serum PON1 was polymorphically distributed [20-22] and a number of 
research demonstrated that the molecular basis of these differences were Q192R, L55M and 
C(-107)T polymorphisms in pon1 gene.  
The pon1 gene contains functional polymorphisms in both the coding and promoter regions. 
In the coding region, two common polymorphism are a glutamine (Q) to arginine (R) 
substitution at codon 192 (Q192R) and a leucine (L) to methionine (M) substitution at 
position 55 (L55M). In Q192R polymorphism the exchange of codon CAA to CGA in exon 6 
of pon1 gene determines isoforms of the enzyme which differ greatly in the rate of 
hydrolysis a number of substrates. Paraoxon is hydrolysed at a far greater rate by the R192 
isoform compared to the Q192, but some organophospates and lactones are hydrolyzed 
faster by Q192 [12,13]. Recent study showed that R isoform of the enzyme has higher 
lactonase activity and increased antiatherogenic potential [23]. 
L55M polymorphism (exchange of codon TTG to ATG in exon 3) is correlated with blood 
enzyme level with isoform L55 associated with higher serum enzymatic activity. Still, it is 
not clear whether this is because of a decreased stability of the M55 alloenzyme [24] and/or 
because of the linkage disequilibrium with -107/-108 T allele [25, 26]. Isoform M55 showed 
lower stability and loses activity more rapidly and to a greater extent than the L isoform 
[24]. This is due to the key role of L55 in packing in the propeller's central tunnel, and of its 
neighboring residues which ligate calcium iones [27]. 
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At least five polymorphisms have been detected in the human pon1 gene promoter region: 
C(-107/-108)T, G(-126)C, G(-162)A, G(-832)A and G(-909)C, but only C(-107T) apear to affects 
expression level of PON1 enzyme [25,26]. This single nucleotide polymorphism (SNP) is 
within stimulating protein-1 (Sp1) binding site with allele T that disrupts the recognition 
sequence for Sp1 and results in decreased affinity for it [28].  
The frequencies of alleles of Q192R, L55M and C(-107)T polymorphisms are different among 
populations worldwide (Table 1). Data for European population showed predominance of 
Q192 and -107C alleles over R192 and -107T alleles. Spanish and Serbian populations 
showed higher frequency of the -107T allele. For codon 55 polymorphism, populations 
worldwide show predominance of L55 over M55 allele. In Asia allele Q192 is more frequent 
only in Indian Punjabis and Iranians and allele -107C is predominant among examined 
populations. Afro-Americans and Amerindian tribes showed higher frequency of allele R 
compared with allele Q and predominance of allele-107C. Only Mexicans showed higher 
frequency of -107T allele. There is a very little data from „black“ continent and it concerns 
only Q192R polymorphism frequency with higher frequency of allele R only in Beninese 
(Table 1). 
More than 200 single nucleotide polymorphisms (SNPs) have been identified in the human 
pon1 gene but only these three have been associated with a number of pathophysiological 
conditions.  
2.3. Pon1 variants and oxidative stress-related disorders  
The central role of HDL is in the process of reverse cholesterol transport (RHC). Also it has 
antioxidative, antiinflammatory and antifibrinolytic functions that contribute to its 
antiatherosclerotic effects. Mackness and coworkers were the first that showed that HDL 
acted at a specific point in the oxidation cascade: it metabolises oxidized phospholipids on 
LDL [29]. Although several other HDL-associated proteins such as apo AI, 
lecithin:cholesterol acyltransferase (LCAT) and platelet-activating factor acetyltransferase 
(PAFAH) also have antioxidant properties, PON1 seems to be the predominant antioxidant 
enzyme [4, 29-31]. HDL isolated from the blood of PON1 knock-out mice or from avian 
species which naturally lack PON1, has at best, no effect on LDL-oxidation and at worst 
promotes LDL-oxidation [32,33]. Conversely, HDL isolated from mice overexpressing 
human PON1 completely abolishes LDL-oxidation [34]. Several human studies have shown 
an inverse linear relationship between the concentration of oxidised-LDL in the circulation 
and PON1 activity, strongly implicating PON1 in the metabolism of oxidised-LDL in vivo 
[35,36].  
Enzymatic and nonenzymatic systems of antioxidative protection are included in 
scavenging free radicals and their metabolic products and in maintaining normal cellular 
physiology. Increased level of free radicals and impairment of antioxidant status are 
processes underlying pathophysiologic mechanisms in a variety of diseases including 
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atherosclerosis, diabetes mellitus, cancer, chronic liver impairment, several neurological 
diseases, many infectious diseases and association studies have identified links between 
pon1 gene polymorphisms and susceptibility and outcome of these diseases.  
pon1 
polymorphisms 
Q192R L55M C(-107)T References 
Q R L M C T  
Populations of Europe 
Finnish 0.69 0.31 0.67 0.33 - - 76 
Dutch 0.68 0.32 0.63 0.37 - - 77 
Spanish 0.7 0.3 0.63 0.37 0.46 0.54 78 
Italians 0.65 0.35 0.66 0.34 0.57 0.43 79 
English 0.78 0.22 0.7 0.3 0.52 0.48 80 
Turkish 0.69 0.31 0.7 0.3 - - 81 
Croatian 0.77 0.23 0.66 0.34 0.54 0.46 82 
Czecs 0.54 0.46 0.69 0.31 0.59 0.41 83 
Serbian 0.77 0.23 0.68 0.32 - - 84 
Populations of Asia 
Asian Indians 
Punjabis 
0.74 0.26 0.81 0.19 0.52 0.48 85 
Japanese 0.4 0.6 0.94 0.06 0.48 0.52 86 
Koreans 0.38 0.620 0.94 0.06 - - 87 
Chinese 0.42 0.58 0.95 0.05 0.57 0.43 88, 89 
Iranian 0.69 0.31 0.59 0.41 - - 90 
Populations of America 
Caucasian-
Americans 
0.73 0.27 0.64 0.36 0.5 0.5 26 
Canadians 0.73 0.27 0.64 0.36 0.48 0.52 91, 28 
African-
Americans 
0.37 0.63 0.79 0.21 0.85 0.15 92 
Amazonian 
Amerindian 
tribes 
0.27 0.730 0.967 0.033 - - 93 
Caribean-
Hispanics 
0.540 0.460 0.71 0.29 0.65 0.35 92 
Mexicans 0.510 0.490 0.84 0.16 0.45 0.55 94 
Peruvians 0.539 0.461 - - 0.61 0.39 95 
Populations of Africa 
Beninese 0.388 0.612 - - - - 96 
Ethiopians 0.592 0.408 - - - - 96 
Egyptians 0.67 0.33 - - - - 97 
Table 1. The allele frequencies of pon1 gene polymorphisms Q192R, L55M and C(-107)T in populations 
worldwide 
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According to World Health Organization (WHO data for 2010), 95% of mortality in Serbia is 
caused by chronic noncontagious diseases, wherefrom 58% of it is caused by cardiovascular 
diseases (CVD) [37]. Although patients with CVD commonly have at least one identifiable 
risk factor, many ischemic events occur in the absence of any of it [38]. Atherogenesis, one of 
the main risk factors for CVD, is initiated by oxidation of the low-density lipoprotein (LDL) 
and by impairment in oxidative stress-antioxidant balance.  
Enhanced oxidative stress such as in diabetes, leads to the development of accelerated 
atherosclerosis. Atherosclerosis in patients with diabetes tends to occur earlier and be more 
aggressive. People with type 2 diabetes have a 3–4 fold increased risk of developing 
atherosclerosis compared to people without type 2 diabetes. Serbia falls into the group of 
European countries with the highest diabetes mortality rates where diabetes is the fifth 
leading cause of death and the fifth cause of the burden of disease [39]. At least a half of the 
persons with non-insulin dependent diabetes mellitus (NIDDM) have not been diagnosed 
and are not aware of their disease [40,41]. 
Due to the abovementioned, there has been a marked interest in discovering additional 
markers of oxidative stress, including gene variants, which may have a role in predicting 
wide spread diseases risk. Because controversial results have been reported so far, the aim 
of studies performed in our laboratory was to evaluate possible interactions between pon1 
gene polymorphisms and clinical manifestations of atherosclerosis and diabetes mellitus 
type 2 in our population.  
Allele and genotype frequencies for Q192R, L55M and C(-107)T did not show significant 
difference between cases with clinical manifestations of atherosclerosis (60 subjects) and 
controls (100 subjects) (P>0.05). Although the M allele (L55M) has shown a somewhat higher 
risk (OR=1.23) and the T allele (-107C/T) has shown a 1.49 times lower risk of occurence of 
the disease (OR=0.67) the difference did not reach statistical significance, most likely due to 
low number of subjects (Grubisa et al., unpublished data). 
Also, we investigated the association between these polymorphisms and atherosclerosis in 
patients with type 2 diabetes mellitus (140 subjects). Our results have shown that R allele is a 
risk factor for atherosclerosis in these patients (OR=2.22, P<0.0001). Although M allele has 
shown a little higher risk (OR=1.26) and allele T has shown a slightly lower risk (OR=0.85) 
the results obtained do not support an association between these pon1 gene variants and 
atherosclerosis in NIDDM patients (Grubisa et al., unpublished data). 
Lactones are hydrolyzed preferentially by either PON1 Q or R isoformes, depending of 
their structure. R192 is more efficient at hydrolyzing homocysteine thiolactone, while δ-
valerolactone and 2-coumaranone are more rapidly hydrolyzed by PON1Q192 [12]. In 
1990's the results obtained indicated that the Q192R polymorphism may play the role in 
coronay heart disease (CHD) etiology because this genotype is associated with LDL 
oxidation; the PON1-192 R isoform is less effective at hydrolysing lipid peroxides than the 
Q isoform [42,43]. It have been shown that position 192 is involved in HDL binding as a 
part of amphipathic helix H2 of active site [27]. Gaidukov and coworkers reported from in 
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vitro and sera tests that the PON1-192Q izoform binds HDL with a 3-fold lower affinity 
than the R isozyme and consequently exhibits significantly reduced stability, 
lipolactonase activity, and macrophage cholesterol efflux [27]. The higher lactonase 
activity is manifested by increased antiatherogenic potency: the observed rate of HDL-
mediated cholesterol efflux from macrophages is 2.2-fold higher for the 192R [27]. Also it 
was shown that the affinity and stability of the PON1 on HDL was lower in sera of 
individuals with the Q192 variant than in individuals with the 192R variant [27]. Low 
levels of HDL particles is one of the strongest risk factors for coronary heart disease and 
one of the characteristic features of diabetic dyslipidemia and it seems that proteins on 
HDL play a major role in the protection against atherosclerois-based cardiovascular 
diseases. HDL carryng apolipoprotein A-I binds PON1 with high affinity,  stabilizes the 
enzyme and stimulates  its lipolactonase activity [44].  
PON1 is also an extracellular homocysteine-thiolactonase (Hcy-thiolactonase). Hcy-
thiolactone is a toxic metabolite linked to immune activation and thrombogenesis in human 
cardiovascular diseases and is elevated under conditions predisposing atherosclerosis [45-
47]. A small fraction of Hcy, a sulfur-containing amino acid, is metabolized to a Hcy-
thiolactone in an error-editing reaction in protein biosynthesis when Hcy is mistakenly 
selected instead of dietary methonine (Met) [48]. Hcy-thiolactone is neutral at physiological 
pH and can diffuse out of the cell and accumulate in the extracellular fluids where is 
hydrolyzed to Hcy by extracellular Hcy-thiolactonase-paraoxonase 1 [49] 
Hcy-thiolactonase activity is strongly associated with pon1 genotype in diverse human 
populations [15]. High Hcy-thiolactonase activity is associated with L55 and R192 alleles, 
more frequent in blacks than in whites and low activity is associated with M55 and Q192 
alleles, more frequent in whites than in blacks [15]. Despite the impact of pon1 genotype on 
Hcy-thiolactonase activity, these genetic variations are not asociated with atherosclerosis-
based cardiovascular diseases. It seems that PON1 phenotype is better predictor [16,50]. 
Human clinical studies suggest that PON1 phenotype, i.e., paraoxonase activity is a much 
stronger predictor of cardiovascular disease status than PON1 genetic polymorphisms [51-
55] a finding that has been confirmed in other studies [52,55]. Bhattacharyya and colleagues 
demonstrated that both the pon1 Q192R polymorphism and serum PON1 activity are 
associated with prevalent coronary artery disease and incident adverse cardiovascular 
events [56]. This study complemented the study of Gaidukov, demonstrating that 
individuals with the arginine (R) at position 192 have higher serum levels of PON1 activity, 
lower systemic indices of systemic oxidative stress and corresponding reductions in both 
prevalent coronary artery disease and prospective cardiac events [56]. Plasma PON1 activity 
can vary up to 40 to 50-fold, and differences in PON1 protein levels up to 13–15-fold are also 
present within a single PON1 Q192R genotype in adults [57,58]. A number of studies 
indicated that measurement of an individual's PON1 function (serum activity) takes into 
account all polymorphism and other factors that might affect PON1 activity or expression. 
However, modulation of PON1 by alcohol, smoking, drugs, diet, certain physiological and 
pathological conditions should also be considered. These factors can increase or decrease 
PON1 activity [59] as well as HDL status. 
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However, PON1 activity is partially inactivated during the detoxification of lipid 
hydroperoxides [60]. This effect can be possibly related to displacement of calcium ions or 
inhibition through free radicals directly. It has been suggested that other antioxidant 
enzymes might prevent this inhibition of PON1 activity. Antioxidant enzymes, all show co-
activity and might work in a collaboration against oxidative stress and elevation in oxidative 
stress might inhibit these enzymes [61].  
Paraoxonases are important detoxifying and anti-oxidative enzymes, which establishes their 
role in organophosphate poisoning, diabetes, obesity, cardiovascular diseases, and innate 
immunity [62, 63] Consequently, PON2 has been the focus of a great deal of research in 
recent years. Both PON1 and PON2 protect against atherosclerosis development and share 
ability to hydrolyze lactones with both overlaping and distinct substrate specificities [19]. 
Although PON1 is associated with circulating serum HDL and reduces oxidative stress in 
lipoproteins, macrophages in arterial walls and in atherosclerotic lesion by its ability to 
hydrolyze specific oxidized lipids, PON2 acts as an intracelullar antioxidant [7,64-68] 
associated with plasma membrane [6-8]. The mechanism how PON2 modulates oxidative 
stress is still unknown, although Altenhöfer demonstrated that PON2 prevents superoxide 
generation, but was ineffective against existing radicals [69]. Oxidative stress affects PON2 
expression too, but additional studies are needed to highlight the PON2 expression level 
under oxidative stress since controversial results both from in vivo and in vitro experiments 
have been reported [6,7,66,70-74]. 
3. Conclusion 
Paraoxonase 1 is found to be associated with HDL particles within circulation and therefore 
promotes some of HDL's functions. There is no consistent evidence for involvement of pon1 
genotypes in atherosclerosis and diabetes mellitus type 2. Studies analyzed the role of pon1 
polymorphisms in oxidative stress-based diseases showed a great variation in ethnics, 
environmental background, age and gender of case and control groups. Allele frequencies 
appeared to be dependent on geographic locations, perhaps also due to genetic drift. Probably 
the effect of each polymorphism alone of he so called oxidative stress-associated genes is not 
strong enough to affect initiation and progression of atherosclerosis as well as PON1 enzyme 
status (activity levels and catalytic efficiency specified by the Q192R polymorphism) [75]. 
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